Close Menu

Breaking News

The researchers' findings suggest that methylation at those sites might have their effect on lung function through its effect on smoking behaviors.

The British Columbia Centre for Disease Control will use genomic analysis to identify the origins and spread of SARS-CoV-2, formerly known as 2019-nCoV.

The agency compiled the evolving list by drawing on information from drug labeling and the published literature and is asking stakeholders to provide feedback.

The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.

Using genome sequence data for more than 2,500 tumors, researchers saw signs that some passenger mutations may act together to influence tumor features and growth.

The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.

The company is developing a platform that is designed to provide an overview of an individual's health based on sequenced genetic data and other metrics.

OpGen, which is acquiring Curetis, said that combined revenue for both companies would have been about $6 million in 2019 had the deal been completed last year.

The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.

The funding comes from the Bill and Melinda Gates Foundation, which previously provided the company with $500,000 for the test's initial development.

Invitae reported $66.3 million in revenues for the fourth quarter, which fell short of the consensus Wall Street estimate of $68.1 million.

The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

S2 Genomics' Singulator platform combines enzymatic and mechanical disruption to produce suspensions of cells or nuclei for downstream applications.

The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.

The MBS NextGenPCR system was distributed by Canon Biomedical in the US until that firm ceased operations early last year.

The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.

For the three months ended Jan. 31, the firm's revenues rose to $1.36 billion from $1.28 billion, beating analysts' average estimate of $1.35 billion.

The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.

University of Manchester and University of Cambridge researchers found SNPs in genes involved in cell survival, estrogen metabolism, and transcriptional control.

Although polygenic risk scores for coronary artery disease can slightly improve standard risk assessment tools, the predicted clinical impact remains small.

The companies will join their respective technologies to provide pharmacogenomic information for patients undergoing genetic testing.

Researchers analyzed the gut microbiome makeup of more than 600 older individuals before and after adhering to their usual diet or a Mediterranean diet for a year.

The single-tube real-time PCR-based test has also received CE marking, according to Seegene, and is now commercially available.

Last week, GenomeWeb's readers were most interested in Trump calling for an 8 percent cut in the NIH budget.

Pages

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.